Literature DB >> 12062251

Muscular dystrophy into the new millennium.

Alan E H Emery1.   

Abstract

Since the identification of the gene for Duchenne muscular dystrophy and its protein product some 15 years ago, the basic defects in all the commoner forms of dystrophy have now been identified. It is thus possible, on the basis of this information, to make a precise diagnosis in an affected individual and to offer accurate genetic counselling and prenatal diagnosis. Now newer technologies are being applied to the investigation of these disorders. These include studies of single nucleotide polymorphisms, microarray analysis and expression profiling, the yeast two-hybrid assay, and proteomics. A great deal of new information is emerging in this way which will hopefully help us to understand the causes of inter-familial and intra-familial variation and particularly pathogenesis, a detailed understanding of which could be the first step in finding effective treatments.

Entities:  

Mesh:

Year:  2002        PMID: 12062251     DOI: 10.1016/s0960-8966(01)00303-0

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  35 in total

Review 1.  Mechanisms of altered Ca²⁺ handling in heart failure.

Authors:  Min Luo; Mark E Anderson
Journal:  Circ Res       Date:  2013-08-30       Impact factor: 17.367

Review 2.  Wnt signaling in skeletal muscle dynamics: myogenesis, neuromuscular synapse and fibrosis.

Authors:  Pedro Cisternas; Juan P Henriquez; Enrique Brandan; Nibaldo C Inestrosa
Journal:  Mol Neurobiol       Date:  2013-09-07       Impact factor: 5.590

Review 3.  Proteomic profiling of x-linked muscular dystrophy.

Authors:  Caroline Lewis; Steven Carberry; Kay Ohlendieck
Journal:  J Muscle Res Cell Motil       Date:  2009-12       Impact factor: 2.698

4.  Human immunoglobulin G for experimental treatment of Duchenne muscular dystrophy.

Authors:  J Zschüntzsch; P Jouvenal; Y Zhang; F Klinker; M Tiburcy; D Malzahn; D Liebetanz; H Brinkmeier; J Schmidt
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

5.  Social/economic costs and health-related quality of life in patients with rare diseases in Europe.

Authors:  Julio López-Bastida; Juan Oliva-Moreno; Renata Linertová; Pedro Serrano-Aguilar
Journal:  Eur J Health Econ       Date:  2016-03-29

6.  Rational design of antisense oligomers to induce dystrophin exon skipping.

Authors:  Chalermchai Mitrpant; Abbie M Adams; Penny L Meloni; Francesco Muntoni; Sue Fletcher; Steve D Wilton
Journal:  Mol Ther       Date:  2009-03-17       Impact factor: 11.454

7.  Inhibition of prostaglandin D synthase suppresses muscular necrosis.

Authors:  Ikuko Mohri; Kosuke Aritake; Hidetoshi Taniguchi; Yo Sato; Shinya Kamauchi; Nanae Nagata; Toshihiko Maruyama; Masako Taniike; Yoshihiro Urade
Journal:  Am J Pathol       Date:  2009-04-09       Impact factor: 4.307

8.  Computer-aided visualization of muscle weakness distribution.

Authors:  Allan J Pieterse; Nicol C Voermans; Hans S Tuinenga; Baziel G M van Engelen
Journal:  J Neurol       Date:  2008-09-03       Impact factor: 4.849

9.  Adaptive Immune Response Impairs the Efficacy of Autologous Transplantation of Engineered Stem Cells in Dystrophic Dogs.

Authors:  Clementina Sitzia; Andrea Farini; Luciana Jardim; Paola Razini; Marzia Belicchi; Letizia Cassinelli; Chiara Villa; Silvia Erratico; Daniele Parolini; Pamela Bella; Joao Carlos da Silva Bizario; Luis Garcia; Marcelo Dias-Baruffi; Mirella Meregalli; Yvan Torrente
Journal:  Mol Ther       Date:  2016-08-10       Impact factor: 11.454

10.  Stem cells from umbilical cord blood do have myogenic potential, with and without differentiation induction in vitro.

Authors:  Tatiana Jazedje; Mariane Secco; Natássia M Vieira; Eder Zucconi; Thomaz R Gollop; Mariz Vainzof; Mayana Zatz
Journal:  J Transl Med       Date:  2009-01-14       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.